Loading...
Market
Percentage increase in Ascendis Pharma's stock price by end of August 2024?
3
Resolution / Starting Odds
0-10% • 25%
10-20% • 25%
20-30% • 25%
Above 30% • 25%
Stock price data from financial news websites such as Bloomberg or Yahoo Finance
Story
FDA Approves Ascendis Pharma's YORVIPATH, Stock Surges 11.8% Premarket
Aug 12, 2024, 11:53 AM
The U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma's YORVIPATH® (Palopegteriparatide) as the first and only treatment for hypoparathyroidism in adults. This approval marks a significant milestone as it fills the gap left by Takeda's withdrawal of its treatment for the same condition. The announcement has led to a notable increase in Ascendis Pharma's stock, which surged over 11.8% in premarket trading. Hypoparathyroidism is a rare hormone disorder, and YORVIPATH® will now be the only approved treatment available in the U.S. for this condition.
View original story
Similar markets
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Below $150 • 25%
$150 - $175 • 25%
$175 - $200 • 25%
Above $200 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Stock increases by more than 10% • 25%
Stock increases by 5-10% • 25%
Stock changes by less than 5% • 25%
Stock decreases • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
No acquisition • 25%
Less than 50% • 25%
50% to 100% • 25%
101% to 150% • 25%
More than 150% • 25%
Yes • 50%
No • 50%
Increase by 0-10% • 25%
Increase by more than 10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%